Question: Can Cushing’s be hereditary? Dr. Findling: No, except in very rare circumstances. There are forms of adrenal Cushing’s that can be hereditary. In cases of bilateral adrenal hyperplasia, both glands are enlarged and have tumors and can be hereditary. This is very rare. Single adrenal tumors are not hereditary. There are some isolated reports… Continue Reading
Category Archives: Doctor’s Articles
Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency – a worldwide patient survey
The aim was to survey current practice in glucocorticoid replacement therapy and self-perceived health outcomes in patients with adrenal insufficiency. Methods: Participants were recruited via patient organizations to respond anonymously to a web-based survey developed by clinical experts. Unique entries were set up for each patient organization enabling geographical localization of the entries.… Continue Reading
Post-Surgical Recovery in Patients With Cushing’s: Results of an Open-Ended Survey
As Dr. Mary Lee Vance described in the summer 2009 newsletter of the Cushing’s Support and Research Foundation (CSRF), post-operative recovery from Cushing’s syndrome can be long and frustrating. Indeed, previous work has shown that patients continue to have subnormal quality of life even after pituitary and adrenal gland function return to normal. To better… Continue Reading
Post-surgical Recovery in Patients with Cushing’s Syndrome: Comparison of Patient Perceptions and Endocrinology Perspectives
Post-operative recovery from Cushing’s syndrome (CS) can be difficult for patients. Although the impaired health-related quality of life in active CS improves after surgical remission, the quality of life does not normalize in all. Despite extensive research on post-surgical recovery from CS, little research has examined the patient experience recovering from remission of CS. In… Continue Reading
Mifepristone (Korlym): First FDA-Approved Medication for the Treatment of Cushing’s Syndrome
On February 17, 2012, the Food and Drug Administration (FDA) approved mifepristone (Korlym) as a once daily oral medication to treat patients with Cushing’s syndrome. The specific indication was for the treatment of elevated blood sugar in patients with Cushing’s syndrome and type 2 diabetes mellitus. Mifepristone was approved for patients who had failed or… Continue Reading
FIND THE RESOURCES YOU NEED AT EVERY STAGE
Connect
Contact Us